
Accuray (ARAY) Stock Forecast & Price Target
Accuray (ARAY) Analyst Ratings
Bulls say
Accuray is a radiation oncology company with a unique and innovative technology, the CyberKnife, that allows for precise and high-dose radiation treatment for various types of cancer. This positions them well in the growing market for cancer treatments, which is expected to reach $220 billion by 2025. Despite facing challenges with market uncertainty and macroeconomic conditions, the company has been able to maintain a solid financial position, with a strong balance sheet and a lower EV/Sales multiple compared to its peers. As such, while maintaining a cautious stance, our outlook for Accuray's stock remains positive.
Bears say
Accuray is facing multiple challenges currently, including geopolitical uncertainty and macroeconomic factors beyond their control, which have led to delays in revenue recognition and a decline in commercial execution. Despite cost-cutting efforts, the company has missed its financial guidance and is facing declining revenue and profitability. With multiple contracting across the MedTech sector and little visibility on a turnaround, it is unlikely that investors will have an appetite for Accuray's stock.
This aggregate rating is based on analysts' research of Accuray and is not a guaranteed prediction by Public.com or investment advice.
Accuray (ARAY) Analyst Forecast & Price Prediction
Start investing in Accuray (ARAY)
Order type
Buy in
Order amount
Est. shares
0 shares